Navigation Links
Dow AgroSciences, World Wide Wheat Agree to Collaborate on Wheat
Date:6/2/2009

INDIANAPOLIS and PHOENIX, June 2 /PRNewswire/ -- Dow AgroSciences, a wholly owned subsidiary of The Dow Chemical Company (NYSE: DOW), and World Wide Wheat (W3) LLC of Phoenix, Arizona, announced today a collaboration agreement for the development and commercialization of advanced germplasm and traits in wheat.

The concept of the collaboration is to couple Dow AgroSciences' expertise in seeds and traits with W3's proprietary wheat germplasm and robust breeding capabilities. Dow AgroSciences' experience in seed and trait commercialization will be leveraged to bring the next generation of wheat to market. W3 brings more than 40 years of plant breeding to the collaboration and will be able to leverage Dow AgroSciences' reach in key global markets such as North America, Latin America, Europe and Australia.

"We are very pleased to be working with W3, an industry leader in wheat breeding, to launch a portfolio of new products in the near future," said Jerome Peribere, president and CEO of Dow AgroSciences. "This collaboration will build upon our current seed portfolio by expanding into wheat -- a very important global crop which supplies a significant amount of the daily nutrition in human diets. And, we look forward to utilizing our R&D breeding and trait technologies such as EXZACT(TM) Precision Technology to bring advancements in productivity and quality to market."

"We are excited to collaborate with Dow AgroSciences, a significant player in seeds and traits," said Sheldon Richardson, chairman and CEO of W3. "With Dow AgroSciences as our partner, we can leverage customer relationships within the food chain and their marketing and commercialization expertise. Our four decades of plant breeding experience brings a wide diversity of germplasm offering of high yielding varieties developed for markets around the world."

About World Wide Wheat (W3)

World Wide Wheat (W3), headquartered in Phoenix, is one of the world's leading independent plant breeding companies whose research is devoted to the improvement of wheat, barley and oats - major food crops of the world. World Wide Wheat operates research stations in 18 countries, producing superior varieties of cereal grains that are not genetically modified. For more information see www.worldwheat.com.

About Dow AgroSciences

Dow AgroSciences LLC, based in Indianapolis, Indiana, USA, is a top-tier agricultural company that combines the power of science and technology with the "Human Element" to constantly improve what is essential to human progress. Dow AgroSciences provides innovative technologies for crop protection, pest and vegetation management, seeds, traits, and agricultural biotechnology to serve the world's growing population. Global sales for Dow AgroSciences, a wholly owned subsidiary of The Dow Chemical Company, are $4.5 billion. Learn more at www.dowagro.com.


'/>"/>
SOURCE Dow AgroSciences
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Georgia Reproductive Specialists Participates in Largest-Ever In Vitro Fertilization Clinical Trial in the World
2. Aspirin Named 8th World Wonder by Majority of Americans
3. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
4. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
5. A Worldwide Phase III Clinical Trial Seeks U.S. Patients to Explore Investigational Drug Phenoxodiol
6. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
7. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
8. WorldHeart Announces Further Milestone in Miniaturized Assist Pump Development
9. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
10. Pivotal Ustekinumab (CNTO 1275) Phase 3 Data to Debut at World Congress of Dermatology Meeting
11. Video: The Arizona Heart Institute Announces the Largest Worldwide Experience with Endoluminal Grafting to Treat Thoracic Aortic Aneurysms and Related Pathologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... Calif. , May 5, 2016  Diagnostic ... a decade due to concerns that these tests ... the approach to imaging, as well as the ... new era of medical peripherals that help health care providers ...   Ampronix  advanced medical imaging is a renowned authorized ...
(Date:5/5/2016)... Research and Markets has announced the addition ... EU Markets"  report to their offering.  ,     (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... the current Positron Emission Tomography (PET) scanner and cyclotron install ... includes France , Germany ... and the United Kingdom . Along ...
(Date:5/5/2016)... , May 5, 2016 ... the addition of the  "Europe Thrombocytopenia ... 2016"  report to their offering.  ... ) , ,The latest research Europe ... - 2016, provides comprehensive insights into ...
Breaking Medicine Technology:
(Date:5/6/2016)... ... May 06, 2016 , ... Expert ... . , Since launching in September, 2014 Sleepopolis has resided at Sleepopolis-mattress-reviews.com ... now include pillows, sheets, mattress toppers, bed frames, and more. , Founder and ...
(Date:5/6/2016)... Utah (PRWEB) , ... May 06, 2016 , ... ... Step, an online provider of career-focused education and corporate training, and the National ... are pleased to announce Maritza Aquino as the second full-tuition scholarship recipient of ...
(Date:5/6/2016)... Washington, DC (PRWEB) , ... May 06, 2016 ... ... Blum, Executive Vice President at CareFirst Blue Cross BlueShield and Former Principal Deputy ... Officer at CareMore - an Anthem Company; Steve Ondra, MD, Chief Medical Officer ...
(Date:5/5/2016)... ... May 05, 2016 , ... Qrono Inc. , a ... development collaboration with the Australian critical medicine company, Phebra Pty Ltd. , ... LAI medicines can offer improved therapeutic benefits over oral formulations, including better bioavailability, ...
(Date:5/5/2016)... Tampa, FL (PRWEB) , ... May 05, 2016 ... ... hospital in Tampa to offer patients with non-valvular atrial fibrillation (A-Fib) an alternative ... (LAAC) Implant. Since first offering the procedure in April of 2015, Florida Hospital ...
Breaking Medicine News(10 mins):